铁蛋白重链亚基纳米载药系统的构建及其特性

Epidermal Growth Factor-Ferritin H-Chain Nanoparticles as Nanocarrier of Doxorubicin

靶向给药能将药物传递到指定位置,从而改变药物的疗效并减少毒副作用。构建了一种具有高度生物安全性的人表皮生长因子-铁蛋白重链亚基纳米粒子(EGF-5Cys-FTH1),该纳米粒子能有效靶向于过表达的表皮生长因子受体(EGFR)的乳腺癌细胞。由于采用了基因突变增加了蛋白的载药位点,所构建的阿霉素/铁蛋白重链亚基(DOX/EGF-5Cys-FTH1)纳米载药系统显示了较高的载药量,即1mol EGF-5Cys-FTH1可载72mol阿霉素,且具有pH可控释放的特性。与游离DOX相比,该载药系统相比于对乳腺癌耐DOX的MCF-7/ADR细胞具有更好的致死作用。这些研究为探索构建蛋白类的载药系统治疗癌症提供了新方法。

Targeted drug delivery can be administered to a specified location, thus change the efficacy of drugs and reduce their side effects. In this paper, epidermal growth factor-ferritin H-chain protein （EGF-SCys-FHT1） nanoparticles are developed, which show targeting ability to breast cancer cells with EGFR expression. Then, doxorubicine （DOX） moleculars were loaded onto those nanoparticles, which results in a high loading capacity of the drug delivery system, that is 1 tool EGF-SCys-FTH1 can load 72 mol DOX due to the insert 5Cys peptides. In addition, the DOX/EGF-SCys-FTH1 nanoparticles show a pH-dependent drug release profile, and they are more toxic to the MCF-7/ADR breast cancer cells compared to free DOX. This work might be extended to load a broad range of therapeutics onto very small protein nanoparticles for cancer treatments.